This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Finnberg, N. Articles by El-Deiry, W. S. Search for Related Content PubMed PubMed Citation Articles by Finnberg, N. Articles by El-Deiry, W. S.

DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis

University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania,¹ University of Toronto, Toronto, Ontario, Canada,² Cold Spring Harbor Laboratory, Cold Spring Harbor, New York³

Received 17 October 2004/ Returned for modification 16 November 2004/ Accepted 2 December 2004

DR5 (also called TRAIL receptor 2 and KILLER) is an apoptosis-inducing membrane receptor for tumor necrosis factor-related apoptosis-inducing ligand (also called TRAIL and Apo2 ligand). DR5 is a transcriptional target of p53, and its overexpression induces cell death in vitro. However, the in vivo biology of DR5 has remained largely unexplored. To better understand the role of DR5 in development and in adult tissues, we have created a knockout mouse lacking DR5. This mouse is viable and develops normally with the exception of having an enlarged thymus. We show that DR5 is not expressed in developing embryos but is present in the decidua and chorion early in development. DR5-null mouse embryo fibroblasts expressing E1A are resistant to treatment with TRAIL, suggesting that DR5 may be the primary proapoptotic receptor for TRAIL in the mouse. When exposed to ionizing radiation, DR5-null tissues exhibit reduced amounts of apoptosis compared to wild-type thymus, spleen, Peyer's patches, and the white matter of the brain. In the ileum, colon, and stomach, DR5 deficiency was associated with a subtle phenotype of radiation-induced cell death. These results indicate that DR5 has a limited role during embryogenesis and early stages of development but plays an organ-specific role in the response to DNA-damaging stimuli.

This article has been cited by other articles:

• Cretney, E., Uldrich, A. P., McNab, F. W., Godfrey, D. I., Smyth, M. J. (2008). No requirement for TRAIL in intrathymic negative selection. Int Immunol 20: 267-276 [Abstract] [Full Text]  
• Daniel, D., Yang, B., Lawrence, D. A., Totpal, K., Balter, I., Lee, W. P., Gogineni, A., Cole, M. J., Yee, S. F., Ross, S., Ashkenazi, A. (2007). Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 110: 4037-4046 [Abstract] [Full Text]  
• Finnberg, N., El-Deiry, W. S. (2006). Selective TRAIL-Induced Apoptosis in Dysplastic Neoplasia of the Colon May Lead to New Neoadjuvant or Adjuvant Therapies.. Clin. Cancer Res. 12: 4132-4136 [Full Text]  
• Rubio-Moscardo, F., Blesa, D., Mestre, C., Siebert, R., Balasas, T., Benito, A., Rosenwald, A., Climent, J., Martinez, J. I., Schilhabel, M., Karran, E. L., Gesk, S., Esteller, M., deLeeuw, R., Staudt, L. M., Fernandez-Luna, J. L., Pinkel, D., Dyer, M. J. S., Martinez-Climent, J. A. (2005). Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 106: 3214-3222 [Abstract] [Full Text]